PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Withdrawal of kidney treatment significantly benefits patients and NHS

2025-08-07
(Press-News.org) Early withdrawal of a treatment for patients with a rare kidney disease is possible without relapse, safer for patients and saves the NHS millions of pounds, new research has revealed.

Atypical Haemolytic Uraemic Syndrome (aHUS) is a life-threatening condition caused by an uncommon defect in the immune system which, in the past, led to kidney failure.

Newcastle University worked with Newcastle Hospitals to carry out clinical trials into the pioneering drug, eculizumab, which led to the NHS approving the treatment from 2015, positively transforming the outlook for patients with the disease.

Now a new study by Newcastle University, UK, funded by the National Institute for Health and Care Research (NIHR) and published today in The Lancet Regional Health Europe, found most patients can stop eculizumab after six months and their disease will not relapse.

Careful monitoring by medical experts allows the drug to be stopped, with the potential to restart the treatment if the disease returns.

The withdrawal of eculizumab is not only of huge benefit to patients’ health and wellbeing but also represents considerable savings to the NHS of £4.2 million per patient over their lifetime.

‘Free from treatment burden’

Neil Sheerin, Professor of Nephrology at Newcastle University and Consultant Nephrologist at The Newcastle Upon Tyne Hospitals NHS Foundation Trust, led the study.

He said: “Our findings are exciting as they have the potential to significantly change the way we manage aHUS and this may be life-changing for some patients.

“Initially, when a patient started treatment for aHUS they faced a lifetime of eculizumab and the dangers associated with it.

“Now we have shown that many people can stop the treatment, freeing them from the burden of regular intravenous injections and removing risk of serious infection associated with the drug.

“In addition, significant efficiency savings for the NHS of £110.4 million over five years could be realised in this patient population through more targeted use of this high-cost treatment.”

When first approved by the National Institute for Health and Care Excellence, it was recommended that patients stay on eculizumab for the rest of their lives unless there was a medical reason to stop.

However, with the treatment, patients have a 500 to 1,000-fold increased risk of meningococcal sepsis and this is immediately eliminated with its withdrawal.

Professor Sheerin added: “What we now have is data to show the withdrawal of eculizumab is safe and effective after an initial six months - this is a huge step forwards in our understanding of the treatment.”

Findings of study

The study was set up to ensure patient safety and 28 participants, aged 2 to 59 from England and Scotland, who had been on eculizumab for at least six months, took part in the trial.

All patients had their treatment withdrawn. Only four participants’ kidney disease returned and the remaining 24 have remained aHus free to date.

Professor Anthony Gordon, Programme Director for the NIHR Health Technology Assessment (HTA) Programme, which funded the trial, said: "Two key priorities for the NIHR are finding the most safe and effective treatments to help people live better, healthier lives for longer, and identify how care can be delivered in the most cost-effective way. 

"The results from this trial show why embedding clinical research within the NHS is so important. Not only do they highlight that eculizumab can be safely withdrawn over time for the majority of aHUS patients, reducing the risk of adverse effects, they also show that potential savings can be made, making the NHS more efficient."

Experts at the National Renal Complement Therapeutics Centre, a collaboration between Newcastle University and Newcastle Hospitals, will continue to monitor patients closely and adapt treatment pathways according to the evidence they generate. 

Professor Sheerin said: “This will allow us to answer important questions, such as can people withdraw again from eculizumab once they’ve relapsed, and can we predict more accurately which people will have a relapse following treatment withdrawal?”

Patient case study

Louise Percival knows first-hand the benefits of being taken off eculizumab.

The 35-year-old was diagnosed with aHus in 2017 and was on the drug until she had it withdrawn as part of the Newcastle University study.

Louise suffered a number of negative side effects from eculizumab, such as regular migraines, hair loss and breathlessness that impacted her daily life.

The pension claims handler, from York, said: “When I was diagnosed with aHUS I felt overwhelmed as it was a huge burden to live with – it was life-changing as it’s something that will never go away.

“I strongly disliked the eculizumab infusions as they had to be given religiously every two weeks, which impacted my holidays and social events.

“I’m a very active person, enjoying hiking and the gym, so the side effects and time needed for the treatment were detrimental to my quality of life.

“Not to mention I have a fear of needles, so having a cannula put in my arm every fortnight was very distressing.”

Louise has successfully stopped eculizumab with no relapses, significantly improving her quality of life.

She said: “All of the side effects disappeared and I feel like myself again.

“Initially, I was told eculizumab would be a lifelong commitment, which felt very daunting. But this amazing research has shown the treatment can successfully be withdrawn and that’s fantastic.”

Reference:

Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial. Andrew Bryant et al. The Lancet Regional Health and Europe. DOI: 10.1016/j.lanepe.2025.101392

Ends

END


ELSE PRESS RELEASES FROM THIS DATE:

Illinois Tech hosts EV Readiness Community Awards, showcasing nation-leading energy innovation

2025-08-07
CHICAGO—August 7, 2025—Illinois Institute of Technology (Illinois Tech) hosted the third annual EV Readiness Community Award Ceremony this week, celebrating 17 local governments across northern Illinois for their leadership in preparing for the transition to electric vehicles (EVs). The ceremony, co-led by ComEd and the Metropolitan Mayors Caucus, brought together mayors, municipal leaders, industry experts, and elected officials to recognize communities that have earned EV Ready designations through actionable local policy, planning, and infrastructure. The event featured remarks from Chicago Mayor Brandon Johnson, Senator Dick Durbin, ...

Rice bioscientist wins NSF CAREER Award to investigate bacterial toxins, expand inclusion in STEM

2025-08-07
When bacteria battle for survival, they do so with microscopic precision. Some produce toxins that target rival microbes, shaping not only their own fitness but the structure of entire microbial communities. Marcos de Moraes, assistant professor of biosciences at Rice University, is fascinated by these microbial skirmishes and how they might be harnessed for biotechnology. Now, with support from the National Science Foundation (NSF) Faculty Early Career Development Program (CAREER), de Moraes will study a little-understood family of bacterial toxins known as deaminases. The five-year, $1.2 million grant will fund research into the molecular ...

Study links exercise with decreased mortality and cardiovascular events in people recently diagnosed with type 2 diabetes but no previous cardiovascular disease

2025-08-07
New research to be presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) shows, among people recently diagnosed with type with type 2 diabetes and no previous cardiovascular disease, a clear association exists between a person’s self-reported physical activity and their risk of all-cause mortality and major adverse cardiac events (MACE), that include heart attacks and strokes. The study is by Ms Line Eriksen and Dr Sidsel Domazet, Steno Diabetes Centre Odense, Odense University ...

Genetic testing reduces risks from chemotherapy for gastrointestinal cancer patients

2025-08-07
PHILADELPHIA— For some patients with gastrointestinal (GI) cancers like colorectal and pancreatic cancer, chemotherapy can cause severe, sometimes life-threatening side effects in those who carry certain genetic variants that can impact how their bodies process the drugs used to treat their disease. Testing for variants in two genes before starting chemotherapy can significantly improve patient safety by providing physicians with information to help tailor doses, according to new research from the Perelman School of Medicine at the University ...

UVic research predicts worldwide glacier erosion

2025-08-07
Glaciers carved the deep valleys of Banff, eroded Ontario to deposit the fertile soils of the Prairies and continue to change the Earth’s surface. But how fast do glaciers sculpt the landscape?   Published today in Nature Geoscience, University of Victoria (UVic) geographer Sophie Norris and her international team provide the most comprehensive view of how fast glaciers erode, and how they change the landscape. Most importantly, their research also provides an estimate of the rate of future erosion for more than 180,000 glaciers worldwide.  Using ...

A new boost for CryoZoo, Barcelona’s animal cell biobank

2025-08-07
The Barcelona CryoZoo is a one-of-a-kind project aiming to safeguard and study biological material from a wide range of animal species – especially those at risk of extinction – in order to preserve and better understand the planet’s biodiversity.  Born out of an initiative by the Barcelona Zoo Foundation, a space managed by BSM through the Barcelona Zoo Foundation, and that is developed jointly with University Pompeu Fabra (UPF), EMBL Barcelona, and the Natural Science Museum of Barcelona, CryoZoo has now been awarded a competitive grant from the wildlife conservation organisation Revive & Restore. This support ...

Asthma drug Zileuton blocks food allergy reactions in mice

2025-08-07
Scientists blocked a newly discovered anaphylaxis pathway in mice using Zileuton Mice went from 95% susceptible to anaphylaxis to 95% protected ‘A totally different, out-of-the-box approach to treat food allergy’ Clinical trial recently launched to test the same approach in humans CHICAGO --- A drug already FDA-approved for asthma was found to nearly eliminate life-threatening allergic reactions to food allergens in mice — a breakthrough that could lead to new protection for millions of people living with food allergies, reports a new Northwestern Medicine ...

Molecules in the spotlight: Snapshots reveal the eternal dance of particles

2025-08-07
FRANKFURT. Most of us find it difficult to grasp the quantum world: According to Heisenberg’s uncertainty principle, it’s like observing a dance without being able to see simultaneously exactly where someone is dancing and how fast they’re moving – you always must choose to focus on one. And yet, this quantum dance is far from chaotic; the dancers follow a strict choreography. In molecules, this strange behavior has another consequence: Even if a molecule should be completely frozen at absolute zero, it never truly comes to rest. The atoms it is made of perform a constant, never-ending quiet dance driven by so-called ...

What drives anaphylactic response in food allergies

2025-08-07
New research in mice reveals that food-induced anaphylaxis is driven by distinct immune pathways involving inflammatory lipids called leukotrienes. The findings, published across two separate studies, identify genetic and cellular factors that influence susceptibility to severe allergic reactions and point to the potential of the drug Zileuton to block this life-threatening response. Food allergies arise when the immune system mounts an exaggerated response to certain proteins found in foods. This reaction is typically driven by Immunoglobulin E (IgE) antibodies, which recognize dietary allergens and activates mast cells throughout the body. In severe ...

A thoughtful approach to governing emerging quantum technologies

2025-08-07
In a Policy Forum, Mateo Aboy and colleagues argue that, instead of turning immediately to rigid regulation to govern emerging quantum technologies, the community should apply a standards-based governance approach tailored to the early, technically focused stage of development. Quantum technologies are poised to revolutionize everything from computing to medicine, offering performance leaps that far surpass the limits of current systems. Yet, this promise comes with complex governance challenges, as these powerful tools ...

LAST 30 PRESS RELEASES:

Home is where the airfields are: What happens when hawks are moved from Los Angeles airports

Study: Sylvester researchers uncover molecular drivers of cellular differentiation

Withdrawal of kidney treatment significantly benefits patients and NHS

Illinois Tech hosts EV Readiness Community Awards, showcasing nation-leading energy innovation

Rice bioscientist wins NSF CAREER Award to investigate bacterial toxins, expand inclusion in STEM

Study links exercise with decreased mortality and cardiovascular events in people recently diagnosed with type 2 diabetes but no previous cardiovascular disease

Genetic testing reduces risks from chemotherapy for gastrointestinal cancer patients

UVic research predicts worldwide glacier erosion

A new boost for CryoZoo, Barcelona’s animal cell biobank

Asthma drug Zileuton blocks food allergy reactions in mice

Molecules in the spotlight: Snapshots reveal the eternal dance of particles

What drives anaphylactic response in food allergies

A thoughtful approach to governing emerging quantum technologies

What makes the teeth of chitons iron hard?

New antibody targeting approach, tested in mice, improves distribution and safety of Alzheimer’s immunotherapies

UC Irvine scientist takes a lesson from ultrahard, wear-resistant mollusk teeth

ICFO researchers overcome long-standing bottleneck in single photon detection with twisted 2D materials

New scaffold technology helps combat traumatic brain injury by restoring copper balance

Bone metastases cultivate immature immune cells to resist immunotherapy

Liming can help enhance carbon capture in agricultural fields

National study urges expanded vaccine screening in emergency departments

Simple color-changing sensor quickly identifies poisonous gases

Exosomes found to play a double role in tumor growth and immune response

Announcing Gordian Biotechnology as Tier 5 Sponsor of ARDD 2025

Disconnection between brain regions explains why some people don’t enjoy music

An interstellar mission to a black hole? Astrophysicist thinks it’s possible.

Earth’s natural CO2 vacuum cleaners

It's not all about size

Cost-effectiveness of 2023-2024 COVID-19 vaccination in US adults

Demographics, lifestyle, comorbidities, prediabetes, and mortality

[Press-News.org] Withdrawal of kidney treatment significantly benefits patients and NHS